Home > Boards > US Listed > Biotechs > Eloxx Pharmaceuticals Inc. (ELOX)

The stock has been moving up quietly over

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
investora2z Member Profile
 
Followed By 10
Posts 602
Boards Moderated 0
Alias Born 02/08/13
160x600 placeholder
Eloxx Announces The Publication of Two Manuscripts on ELX-02 and It’s ERSG Library In Two Leading Journals GlobeNewswire Inc. - 10/27/2020 7:30:10 AM
Eloxx Presents Two Preclinical Posters at the 2020 North American Cystic Fibrosis Virtual Conference GlobeNewswire Inc. - 10/22/2020 8:57:31 AM
Eloxx Pharmaceuticals to Report Third Quarter 2020 Financial Results and Provide Business Update on November 5, 2020 GlobeNewswire Inc. - 10/15/2020 7:00:10 AM
Globally Renowned Cystic Fibrosis Expert, Dr. Eitan Kerem, Joins Eloxx Pharmaceuticals as a Senior Consultant GlobeNewswire Inc. - 9/14/2020 10:06:20 AM
Eloxx Announces Two Preclinical Abstracts Accepted for Presentation at the 2020 North American Cystic Fibrosis Virtual Confer... GlobeNewswire Inc. - 8/26/2020 7:30:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/12/2020 7:55:55 AM
Enrollment in the U.S. Phase 2 Clinical Trial in Cystic Fibrosis Has Resumed After Being Paused in Response to the COVID-19 P... GlobeNewswire Inc. - 8/12/2020 7:30:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/6/2020 8:16:56 AM
Eloxx Pharmaceuticals Reports Second Quarter 2020 Financial and Operating Results and Provides Business Update GlobeNewswire Inc. - 8/6/2020 7:30:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/4/2020 7:51:30 AM
Eloxx Pharmaceuticals Receives U.S. Orphan Drug Designation for ELX-02 for the Treatment of Cystic Fibrosis GlobeNewswire Inc. - 8/4/2020 7:30:10 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/31/2020 4:11:16 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/31/2020 4:11:05 PM
Eloxx Pharmaceuticals to Present at the 40th Annual Canaccord Genuity Virtual Growth Conference on August 13th, 2020 GlobeNewswire Inc. - 7/28/2020 12:33:50 PM
Eloxx Pharmaceuticals to Report Second Quarter 2020 Financial Results and Provide Business Update on August 6, 2020 GlobeNewswire Inc. - 7/21/2020 2:17:29 PM
Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Pharmacology and Experimental Therapeutics GlobeNewswire Inc. - 7/15/2020 1:08:32 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/17/2020 4:47:30 PM
Enrollment in Phase 2 Clinical Trial in Cystic Fibrosis Has Been Resumed in Israel and Europe After Being Paused Temporarily ... GlobeNewswire Inc. - 6/17/2020 4:01:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/26/2020 3:04:27 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:12:16 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:11:59 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:11:53 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:11:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:11:32 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/22/2020 4:11:25 PM
investora2z   Sunday, 11/24/13 06:32:22 AM
Re: None
Post # of 773 
The stock has been moving up quietly over the last one week. It may make a stronger move after the update on the trials is announced early next month. Senesco's platform technology has a lot of potential, and the trial results so far have confirmed that the possibilities are tremendous. This is especially true if one considers the huge market for cancer drugs. Factor 5A can regulate programmed cell death and cell survival through controlling the expression of pro and anti-apoptotic proteins. The initial use of the technology was to extend shelf life of food and increase crop yield, but the inverse activation of Factor 5A also had huge possibilities for the treatment of cancer. The main drug candidate SNS01T targets B-cell cancers by selectively inducing programmed cell death (apoptosis) using Factor 5A. Cancer therapy trials focus on multiple myeloma and other B-cell cancers. SNS01T has been found to inhibit the growth and even shrink tumors of human B-cell cancers in animal models. SNS01T has an orphan drug status granted by USFDA. The company has numerous patents related to Factor 5A platform. The use in agricultural biotechnology and biofuels development also holds a lot of promise. It has collaborations with big companies like Bayer Crop Science and Monsanto to name a few. In addition to increasing seed yield and plant size, the technology can provide resistance against premature cell death caused by environmental stresses like frost, drought, heat, and soil salinity. According to the arrangements, Senesco is entitled to earn R&D milestones and royalties if their technology is used by the partners. Even the last 10Q contained a milestone payment of $100K. However, the trials and approval will take time and will require funding. The cancer treatment related trials & approvals may take a couple of years. Meanwhile, the agricultural licensing revenues can provide some cash flow, but the company will require external funding from time to time to pursue its research.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences